Dynamic changes in vasohibin and nitric oxide signaling following surgical resection of head and neck squamous cell carcinoma

Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced an...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of surgical oncology Vol. 23; no. 1; pp. 221 - 11
Main Authors Tai, Ying-Hsuan, Wu, Hsiang-Ling, Chu, You-Hsiang, Wu, Cheng-Hsien, Tai, Shyh-Kuan, Lin, Tso-Chou, Ho, Shung-Tai, Lu, Chih-Cherng
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 07.06.2025
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection. We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting. Patients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL vs. 2425 ± 1493 pg·mL , p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds. This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control.
AbstractList Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection.BACKGROUNDAngiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection.We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting.METHODSWe prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting.Patients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL-1 vs. 2425 ± 1493 pg·mL-1, p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds.RESULTSPatients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL-1 vs. 2425 ± 1493 pg·mL-1, p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds.This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control.CONCLUSIONSThis study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control.
Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection. We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting. Patients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL vs. 2425 ± 1493 pg·mL , p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds. This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control.
Abstract Background Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection. Methods We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting. Results Patients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL−1 vs. 2425 ± 1493 pg·mL−1, p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds. Conclusions This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control.
Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection. We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting. This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control.
Background Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection. Methods We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting. Results Patients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL.sup.-1 vs. 2425 ± 1493 pg·mL.sup.-1, p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds. Conclusions This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control. Keywords: Angiogenesis, Biomarker, Head and neck cancer, Nitric oxide, Vasohibin
ArticleNumber 221
Audience Academic
Author Wu, Cheng-Hsien
Lin, Tso-Chou
Tai, Shyh-Kuan
Lu, Chih-Cherng
Tai, Ying-Hsuan
Ho, Shung-Tai
Chu, You-Hsiang
Wu, Hsiang-Ling
Author_xml – sequence: 1
  givenname: Ying-Hsuan
  surname: Tai
  fullname: Tai, Ying-Hsuan
– sequence: 2
  givenname: Hsiang-Ling
  surname: Wu
  fullname: Wu, Hsiang-Ling
– sequence: 3
  givenname: You-Hsiang
  surname: Chu
  fullname: Chu, You-Hsiang
– sequence: 4
  givenname: Cheng-Hsien
  surname: Wu
  fullname: Wu, Cheng-Hsien
– sequence: 5
  givenname: Shyh-Kuan
  surname: Tai
  fullname: Tai, Shyh-Kuan
– sequence: 6
  givenname: Tso-Chou
  surname: Lin
  fullname: Lin, Tso-Chou
– sequence: 7
  givenname: Shung-Tai
  surname: Ho
  fullname: Ho, Shung-Tai
– sequence: 8
  givenname: Chih-Cherng
  surname: Lu
  fullname: Lu, Chih-Cherng
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40483461$$D View this record in MEDLINE/PubMed
BookMark eNptkstq3TAQhk1JaZLTvkAXRVAo3TjVxZLsVQlJL4FAN-1ajGXZR6ksJZKdNIu8e-U4DedA0ULD6Jsfzcx_XBz44E1RvCX4hJBafEqENlyWmPISs5qzsn5RHJFKylLWpDnYiQ-L45SuMKaMcfaqOKxwVbNKkKPi4fzew2g10lvwg0nIenQLKWxtmyPwHfJ2ivk9_LGdQckOHpz1A-qDc-FuidIcB6vBoWiS0ZMNHoUebQ10a73Rv1G6mWEMc0LaOIc0RG19GOF18bIHl8ybp3tT_Pr65efZ9_Lyx7eLs9PLUnOKp5IIgUXTsI5TLgyrGG2x0C0hbctkBz3XDdRMN9IQpiUXvCUVlZJzLohom5ZtiotVtwtwpa6jHSHeqwBWPSZCHBTEyWpnFDa8o7LDBEtTNSCANdAabqSgugKGs9bnVet6bkfTaeOnCG5PdP_F260awq0ilFSVzAvYFB-fFGK4mU2a1GjTMhjwJs9IMZobbgSuZUbfr-gA-W_W9yFL6gVXp3XFMKeyXgRP_kPl05m82mya3ub8XsGHnYK8KjdtU3Dzsry0D77bbfa5y38GygBdAR1DStH0zwjBanGpWl2qskvVo0tVzf4CytzYzQ
Cites_doi 10.3892/or.2017.5746
10.1007/s12032-012-0212-1
10.4103/jcrt.jcrt_281_21
10.1200/JCO.2001.19.4.1207
10.1186/s12957-020-01991-9
10.1007/s10495-023-01832-6
10.1111/cas.14041
10.1016/j.oraloncology.2020.104977
10.1007/s12032-011-0106-7
10.1016/j.heliyon.2024.e30877
10.1111/j.1349-7006.2009.01483.x
10.1136/jclinpath-2013-201444
10.1038/nrc.2017.51
10.1016/j.oraloncology.2008.03.009
10.32471/exp-oncology.2312-8852.vol-41-no-3.13515
10.3390/ijms21249393
10.1177/01455613221078184
10.1158/1541-7786.MCR-12-0098-T
10.1111/j.1349-7006.2009.01388.x
10.1016/j.critrevonc.2022.103805
10.1038/bjc.2013.169
10.15761/GIMCI.1000132
10.1016/j.niox.2022.07.006
10.1016/j.canlet.2016.11.016
10.1620/tjem.243.107
10.1186/s12964-014-0062-x
10.3892/etm.2017.4969
10.1186/1476-4598-13-99
10.2353/ajpath.2009.080788
10.1111/micc.12608
10.1038/sj.cr.7290133
10.1182/blood.V94.11.3717
10.21873/anticanres.11437
10.1007/s11912-019-0799-x
10.1007/s00595-020-02040-4
10.1177/0022034518756297
10.1172/JCI200421152
10.1080/15384047.2017.1373217
ContentType Journal Article
Copyright 2025. The Author(s).
COPYRIGHT 2025 BioMed Central Ltd.
The Author(s) 2025 2025
Copyright_xml – notice: 2025. The Author(s).
– notice: COPYRIGHT 2025 BioMed Central Ltd.
– notice: The Author(s) 2025 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/s12957-025-03853-8
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE




Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1477-7819
EndPage 11
ExternalDocumentID oai_doaj_org_article_0e5d27d0107e49a6a39abe5e762c4a30
PMC12144735
A843052785
40483461
10_1186_s12957_025_03853_8
Genre Journal Article
GeographicLocations Taiwan
GeographicLocations_xml – name: Taiwan
GrantInformation_xml – fundername: Taipei Veterans General Hospital
  grantid: V110C-086
GroupedDBID ---
0R~
29R
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
IAO
IHR
IHW
INH
INR
ITC
KQ8
M1P
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7X8
PPXIY
5PM
PJZUB
PUEGO
ID FETCH-LOGICAL-c520t-16606993d5256e3432b06cb11bb37daf5c9a83c97e13c7565b14277555616b9b3
IEDL.DBID DOA
ISSN 1477-7819
IngestDate Wed Aug 27 01:25:20 EDT 2025
Thu Aug 21 18:25:21 EDT 2025
Fri Jul 11 17:13:15 EDT 2025
Thu Jun 19 01:37:35 EDT 2025
Tue Jun 17 03:40:44 EDT 2025
Tue Jun 17 02:10:56 EDT 2025
Thu Jun 12 01:53:13 EDT 2025
Thu Jul 03 08:14:32 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Angiogenesis
Head and neck cancer
Biomarker
Nitric oxide
Vasohibin
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c520t-16606993d5256e3432b06cb11bb37daf5c9a83c97e13c7565b14277555616b9b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/0e5d27d0107e49a6a39abe5e762c4a30
PMID 40483461
PQID 3216696087
PQPubID 23479
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_0e5d27d0107e49a6a39abe5e762c4a30
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12144735
proquest_miscellaneous_3216696087
gale_infotracmisc_A843052785
gale_infotracacademiconefile_A843052785
gale_healthsolutions_A843052785
pubmed_primary_40483461
crossref_primary_10_1186_s12957_025_03853_8
PublicationCentury 2000
PublicationDate 2025-06-07
PublicationDateYYYYMMDD 2025-06-07
PublicationDate_xml – month: 06
  year: 2025
  text: 2025-06-07
  day: 07
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle World journal of surgical oncology
PublicationTitleAlternate World J Surg Oncol
PublicationYear 2025
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References Z Shen (3853_CR11) 2012; 29
YH Tai (3853_CR23) 2020; 27
D Li (3853_CR29) 2010; 101
H Hara (3853_CR35) 2020; 50
M De Palma (3853_CR1) 2017; 17
P Salven (3853_CR41) 1999; 5
X Xue (3853_CR7) 2014; 12
Y Takahashi (3853_CR8) 2012; 10
G Zhao (3853_CR3) 2017; 38
A Aguayo (3853_CR40) 1999; 94
Q Wang (3853_CR15) 2012; 29
LB Schmitd (3853_CR20) 2018; 97
AW Girotti (3853_CR9) 2022; 179
M Vakkala (3853_CR17) 2000; 6
HB Jones (3853_CR19) 2009; 45
E Kopczyńska (3853_CR25) 2012; 2012
S Dios-Barbeito (3853_CR10) 2022; 128
FH Khan (3853_CR38) 2020; 21
M Zhang (3853_CR32) 2024; 10
S Kitahara (3853_CR6) 2014; 13
T Kosaka (3853_CR26) 2013; 108
C Torii (3853_CR12) 2017; 37
N Kanomata (3853_CR14) 2013; 66
B Zhang (3853_CR27) 2017; 14
S Liu (3853_CR28) 2022; 18
DK Zanoni (3853_CR21) 2019; 21
M Tu (3853_CR34) 2017; 388
R Sano (3853_CR13) 2017; 243
W Xu (3853_CR36) 2002; 12
K Watanabe (3853_CR2) 2004; 114
AM Elbehi (3853_CR30) 2020; 109
RT Poon (3853_CR39) 2001; 19
HL Wu (3853_CR18) 2020; 18
T Hosaka (3853_CR4) 2009; 175
VV Holotiuk (3853_CR37) 2019; 41
K Tamaki (3853_CR16) 2010; 101
Y Suzuki (3853_CR22) 2016; 1
R Iida-Norita (3853_CR5) 2019; 110
Z Xu (3853_CR31) 2023; 28
H Du (3853_CR24) 2017; 18
J Liu (3853_CR33) 2024; 103
References_xml – volume: 38
  start-page: 1021
  year: 2017
  ident: 3853_CR3
  publication-title: Oncol Rep
  doi: 10.3892/or.2017.5746
– volume: 29
  start-page: 2718
  year: 2012
  ident: 3853_CR11
  publication-title: Med Oncol
  doi: 10.1007/s12032-012-0212-1
– volume: 18
  start-page: 567
  year: 2022
  ident: 3853_CR28
  publication-title: J Cancer Res Ther
  doi: 10.4103/jcrt.jcrt_281_21
– volume: 19
  start-page: 1207
  year: 2001
  ident: 3853_CR39
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2001.19.4.1207
– volume: 18
  start-page: 209
  year: 2020
  ident: 3853_CR18
  publication-title: World J Surg Oncol
  doi: 10.1186/s12957-020-01991-9
– volume: 28
  start-page: 860
  year: 2023
  ident: 3853_CR31
  publication-title: Apoptosis
  doi: 10.1007/s10495-023-01832-6
– volume: 110
  start-page: 2296
  year: 2019
  ident: 3853_CR5
  publication-title: Cancer Sci
  doi: 10.1111/cas.14041
– volume: 109
  start-page: 104977
  year: 2020
  ident: 3853_CR30
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2020.104977
– volume: 2012
  start-page: 638352
  year: 2012
  ident: 3853_CR25
  publication-title: ISRN Oncol
– volume: 29
  start-page: 2727
  year: 2012
  ident: 3853_CR15
  publication-title: Med Oncol
  doi: 10.1007/s12032-011-0106-7
– volume: 10
  start-page: e30877
  year: 2024
  ident: 3853_CR32
  publication-title: Heliyon
  doi: 10.1016/j.heliyon.2024.e30877
– volume: 101
  start-page: 1051
  year: 2010
  ident: 3853_CR16
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2009.01483.x
– volume: 66
  start-page: 613
  year: 2013
  ident: 3853_CR14
  publication-title: J Clin Pathol
  doi: 10.1136/jclinpath-2013-201444
– volume: 17
  start-page: 457
  year: 2017
  ident: 3853_CR1
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2017.51
– volume: 45
  start-page: 10
  year: 2009
  ident: 3853_CR19
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2008.03.009
– volume: 41
  start-page: 210
  year: 2019
  ident: 3853_CR37
  publication-title: Exp Oncol
  doi: 10.32471/exp-oncology.2312-8852.vol-41-no-3.13515
– volume: 21
  start-page: 9393
  year: 2020
  ident: 3853_CR38
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21249393
– volume: 103
  start-page: 650
  issue: 10
  year: 2024
  ident: 3853_CR33
  publication-title: Ear Nose Throat J
  doi: 10.1177/01455613221078184
– volume: 10
  start-page: 1135
  year: 2012
  ident: 3853_CR8
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-12-0098-T
– volume: 101
  start-page: 448
  year: 2010
  ident: 3853_CR29
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2009.01388.x
– volume: 179
  start-page: 103805
  year: 2022
  ident: 3853_CR9
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2022.103805
– volume: 108
  start-page: 2123
  year: 2013
  ident: 3853_CR26
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2013.169
– volume: 1
  start-page: 1
  year: 2016
  ident: 3853_CR22
  publication-title: Gen Intern Med Clin Innov
  doi: 10.15761/GIMCI.1000132
– volume: 128
  start-page: 1
  year: 2022
  ident: 3853_CR10
  publication-title: Nitric Oxide
  doi: 10.1016/j.niox.2022.07.006
– volume: 5
  start-page: 487
  year: 1999
  ident: 3853_CR41
  publication-title: Clin Cancer Res
– volume: 388
  start-page: 187
  year: 2017
  ident: 3853_CR34
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2016.11.016
– volume: 243
  start-page: 107
  year: 2017
  ident: 3853_CR13
  publication-title: Tohoku J Exp Med
  doi: 10.1620/tjem.243.107
– volume: 12
  start-page: 62
  year: 2014
  ident: 3853_CR7
  publication-title: Cell Commun Signal
  doi: 10.1186/s12964-014-0062-x
– volume: 14
  start-page: 3477
  year: 2017
  ident: 3853_CR27
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2017.4969
– volume: 13
  start-page: 99
  year: 2014
  ident: 3853_CR6
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-13-99
– volume: 175
  start-page: 430
  year: 2009
  ident: 3853_CR4
  publication-title: Am J Pathol
  doi: 10.2353/ajpath.2009.080788
– volume: 27
  start-page: e12608
  year: 2020
  ident: 3853_CR23
  publication-title: Microcirculation
  doi: 10.1111/micc.12608
– volume: 6
  start-page: 2408
  year: 2000
  ident: 3853_CR17
  publication-title: Clin Cancer Res
– volume: 12
  start-page: 311
  year: 2002
  ident: 3853_CR36
  publication-title: Cell Res
  doi: 10.1038/sj.cr.7290133
– volume: 94
  start-page: 3717
  year: 1999
  ident: 3853_CR40
  publication-title: Blood
  doi: 10.1182/blood.V94.11.3717
– volume: 37
  start-page: 1219
  year: 2017
  ident: 3853_CR12
  publication-title: Anticancer Res
  doi: 10.21873/anticanres.11437
– volume: 21
  start-page: 52
  year: 2019
  ident: 3853_CR21
  publication-title: Curr Oncol Rep.
  doi: 10.1007/s11912-019-0799-x
– volume: 50
  start-page: 1530
  year: 2020
  ident: 3853_CR35
  publication-title: Surg Today
  doi: 10.1007/s00595-020-02040-4
– volume: 97
  start-page: 742
  year: 2018
  ident: 3853_CR20
  publication-title: J Dent Res
  doi: 10.1177/0022034518756297
– volume: 114
  start-page: 898
  year: 2004
  ident: 3853_CR2
  publication-title: J Clin Invest
  doi: 10.1172/JCI200421152
– volume: 18
  start-page: 827
  year: 2017
  ident: 3853_CR24
  publication-title: Cancer Biol Ther
  doi: 10.1080/15384047.2017.1373217
SSID ssj0023353
Score 2.3794458
Snippet Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide...
Background Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible...
Abstract Background Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 221
SubjectTerms Adult
Aged
Angiogenesis
Angiogenic Proteins
Biomarker
Biomarkers, Tumor - blood
Biomarkers, Tumor - metabolism
Care and treatment
Case-Control Studies
Cell Cycle Proteins - blood
Cell Cycle Proteins - metabolism
Cellular signal transduction
Female
Follow-Up Studies
Head and neck cancer
Head and Neck Neoplasms - blood
Head and Neck Neoplasms - metabolism
Head and Neck Neoplasms - pathology
Head and Neck Neoplasms - surgery
Health aspects
Humans
Leukocytes - metabolism
Male
Middle Aged
Neovascularization
Neovascularization, Pathologic - metabolism
Neovascularization, Pathologic - pathology
Nitric oxide
Nitric Oxide - blood
Nitric Oxide - metabolism
Nitric Oxide Synthase Type II - blood
Nitric Oxide Synthase Type II - metabolism
Phosphorylation
Prognosis
Prospective Studies
Proteases
Signal Transduction
Squamous cell carcinoma
Squamous Cell Carcinoma of Head and Neck - blood
Squamous Cell Carcinoma of Head and Neck - metabolism
Squamous Cell Carcinoma of Head and Neck - pathology
Squamous Cell Carcinoma of Head and Neck - surgery
Vasohibin
Title Dynamic changes in vasohibin and nitric oxide signaling following surgical resection of head and neck squamous cell carcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/40483461
https://www.proquest.com/docview/3216696087
https://pubmed.ncbi.nlm.nih.gov/PMC12144735
https://doaj.org/article/0e5d27d0107e49a6a39abe5e762c4a30
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-6gnhZ_La6jhEED1K2bZqPHnd0l0XYRRYXBi8hX2UHsXW3M-rF_933ks4wxYMXL6U0aWnyvpO83yPkjeO-YrIIuWCS57UQNgc7A1FKUZemUF76uHt-di5OL-uPC77YKfWFZ8ISPHCauMMiwNekh7BBhroxwrDG2MADCLGrDYvROti8TTA1hlqMcbZJkVHicACrxmWOpVtxJ4zlamKGIlr_3zp5xyhND0zuWKCT-2R_dB3pUfrlB-RW6B6Su2fj5vgj8vtDqi5PUzLvQJcd_WGG_moJ0S81nacgvqD2aP9r6QPFkxsGk9FpC7zQ_8S7YX0TNSHFpKSY8UD7loK-9un94L7S4XptcL2A4po_dViLqOu_mcfk8uT48_vTfKyukDteFau8FBC7gHfiOXg9AfNLbSGcLUtrmfSm5a4xirlGhpI5CX4fLhdJybGeprCNZU_IXtd34RmhHmH-msoHqULtTa1aH1oL5rcMoECakJF3m8nW3xOIho7BhxI6kUYDaXQkjVYZmSM9tj0RADs-ALbQI1vof7FFRl4hNXXKJt2KsT5SiHFWScUz8jb2QEEGojoz5iPAkBASa9LzYNITBNBNml9vOEZjE55a6wLQQbMKJhlCRCUz8jRx0HZUNWL516LMiJrw1mTY05ZueRXxv0uEuZOMP_8fE_WC3KuiXIi8kAdkb3WzDi_Bz1rZGbktF3JG7syPzz9dzKKAwfVi_uUPj4goZQ
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dynamic+changes+in+vasohibin+and+nitric+oxide+signaling+following+surgical+resection+of+head+and+neck+squamous+cell+carcinoma&rft.jtitle=World+journal+of+surgical+oncology&rft.au=Tai%2C+Ying-Hsuan&rft.au=Wu%2C+Hsiang-Ling&rft.au=Chu%2C+You-Hsiang&rft.au=Wu%2C+Cheng-Hsien&rft.date=2025-06-07&rft.issn=1477-7819&rft.eissn=1477-7819&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12957-025-03853-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12957_025_03853_8
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7819&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7819&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7819&client=summon